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The obligate intracellular pathogen Chlamydia tra-
chomatis is the most common cause of sexually
transmitted bacterial disease. It secretes a protease
known as chlamydial protease/proteasome-like
activity factor (CPAF) that degrades many host mol-
ecules and plays a major role in Chlamydia patho-
genesis. Here, we show that mature CPAF is a
homodimer of the catalytic domains, each of which
comprises two distinct subunits. Dormancy of the
CPAF zymogen ismaintained by an internal inhibitory
segment that binds the CPAF active site and blocks
its homodimerization. CPAF activation is initiated
by trans-autocatalytic cleavage, which induces ho-
modimerization and conformational changes that
assemble the catalytic triad. This assembly leads to
two autocatalytic cleavages and removal of the inhib-
itory segment, enabling full CPAF activity. CPAF is
covalently bound and inhibited by the proteasome
inhibitor lactacystin. These results reveal the activa-
tion mechanism of the CPAF serine protease and
suggest new opportunities for anti-Chlamydia drug
development.
INTRODUCTION
Chlamydiae represent a group of obligate intracellular bacterial
pathogens, consisting of multiple species infecting a wide range
of animal hosts. Of medical importance are the species Chla-
mydia trachomatis and Chlamydia pneumoniae. C. trachomatis
infect humans in both the ocular epithelia, causing preventable
blindness, and urogenital tract epithelia, being a leading cause
of sexually transmitted bacterial diseases with 90 million new
cases each year worldwide (Brunham and Rey-Ladino, 2005).
Women infected with C. trachomatis in the urogenital tract can
develop pelvic inflammatory diseases, ectopic pregnancy, and
infertility. The C. pneumoniae are common respiratory patho-
gens in humans (Brunham and Rey-Ladino, 2005), and respira-
tory infection with C. pneumoniae is associated with cardiovas-
cular diseases and pathologies in other systems (Belland et al.,
2004; Campbell and Kuo, 2004; Danesh et al., 1997).Cell HostDespite the severe health problems posed by chlamydial in-
fection, the pathogenic mechanisms are still not well under-
stood. It is believed that Chlamydia-induced diseases largely re-
sult from inflammatory responses provoked during chlamydial
infection (Morrison et al., 1989; Rasmussen et al., 1997; Ste-
phens, 2003). To survive in the infected hosts, Chlamydia has
evolved diverse strategies to escape host immune responses
(Dean and Powers, 2001; Fan et al., 1998; Greene et al., 2004;
Perfettini et al., 2002; Zhong et al., 1999, 2000, and 2001). Chla-
mydia can evade both immune recognition and immune effector
mechanisms by suppressing major histocompatibility complex
(MHC) antigen expression and blocking apoptosis in the infected
cells (Byrne and Ojcius, 2004; Fan et al., 1998; Fischer et al.,
2004; Greene et al., 2004; Miyairi and Byrne, 2006). A Chla-
mydia-secreted protease designated as chlamydial protease/
proteasome-like activity factor (CPAF) contributes to Chlamydia
for evading host defenses by degrading host transcription fac-
tors, the regulatory factor X 5 (RFX5), and upstream stimulation
factor 1 (USF-1) that are required for MHC antigen expression
(Zhong et al., 2001). Degradation of the proapoptotic BH3-only
proteins by CPAF (Pirbhai et al., 2006; Paschen et al., 2008)
can play a role in blocking apoptosis in the infected cells. In
addition, CPAF can also cleave cytokeratin 8, which may aid in
chlamydial inclusion expansion (Dong et al., 2004a).
CPAF is a conserved molecule among chlamydial species and
synthesized as a catalytically inactive zymogen with a molecular
weight of 70 kDa. However, the active CPAF is composed of
a 29 kDa N-terminal (CPAFn) and a 35 kDa C-terminal fragment
(CPAFc) (Dong et al., 2004b) and is notably shorter than the zy-
mogen. Cleavage of the full-length CPAF into CPAFc/n and intra-
molecular dimerization are both necessary and sufficient for con-
version of CPAF zymogen into its active form (Dong et al.,
2004c), which is likely an autocatalytic process (Paschen et al.,
2008). This activation mechanism is highly conserved among
CPAFs from different chlamydial species (Shaw et al., 2002;
Dong et al., 2005) and biologically relevant since CPAF from
the clinical isolates is also processed into CPAFc and CPAFn
(Dong et al., 2004b).
Although it is clear that CPAF is capable of proteolytically tar-
geting various different host molecules, the mechanisms under-
lying CPAF activation and catalysis are unknown. In this study,
we carried out biochemical and structural characterizations
of CPAF and found that CPAF is a serine (Ser) protease with
a water-mediated catalytic triad and a fully active CPAF is& Microbe 4, 529–542, December 11, 2008 ª2008 Elsevier Inc. 529
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Crystal Structures of a Protease from ChlamydiaeFigure 1. Autocatalytic Cleavage of CPAF Zymogen Induces Its Activation and Formation of a Stable Homodimer in Solution
All of the proteins were visualized by Coomassie blue staining following SDS-PAGE.
(A) The CPAF zymogen undergoes autocatalytic cleavages and produces the mature enzyme. (Top) CPAF was incubated at room temperature for the time as
indicated, and then an equal volume of 23 SDS buffer was added. CPAFc1, CPAFc2, and CPAFc start with residues Arg243, Val265, and Gly284, respectively.
(Right) Autocatalytic cleavage of CPAF is concentration dependent. CPAF zymogen proteins with different concentration as indicated were incubated at room
temperature for 3 hr before an equal volume of 2 3 SDS buffer was added.
(B) The autocleaved CPAF actively degrades the CPAF substrate, RFX5. Proteins shown on the left panel of (A) were taken out at different time points and diluted
20-fold for the activity assay. The diluted CPAF was incubated with its substrate RFX5 (residues 181–616) at 4C for 5 min.
(C) The activity of CPAF to degrade RFX5 is inhibited by the proteasome-specific inhibitor lactacystin. CPAF was incubated (for 20 min) with a different concen-
tration of lactacystin, as indicated, before the substrate RFX5 was added.
(D) Autocleavage of CPAF induces its homodimerization. The wild-type CPAF zymogen exists primarily as a monomer, but the autocleaved CPAF exists as a
homodimer in solution. Shown on the left panel is a superposition of the gel filtration chromatograms for the CPAF zymogen (red) and the purified autocleaved
CPAF (blue), and the right panel shows the peak fractions. MW, molecular weight (kDa).a homodimer (CPAFc/n:CPAFc/n). Activation of CPAF is initiated
by sequential autocatalytic cleavages of an internal inhibitory
segment that binds to the active site of CPAF and blocks its ho-
modimerization. A variant of the inhibitory segment interacted
with thematureCPAFand inhibited its activity in vitro. The current
study has provided both the molecular basis for understanding
how CPAF contributes to chlamydial pathogenesis and the es-
sential information for developing specific inhibitors to regulate
CPAFactivity andpotentially attenuate chlamydial pathogenicity.530 Cell Host & Microbe 4, 529–542, December 11, 2008 ª2008 ElsRESULTS
Concentration-Dependent Autocatalytic Cleavages
of CPAF Induce Its Activation
Although purified CPAF (residues 25–609) initially existed as
a single-chain protein, it quickly underwent autocatalytic cleav-
ages to generate CPAFn and CPAFc when incubated at room
temperature, with two intermediates (labeled as CPAFc1 and
CPAFc2) preceding the formation of CPAFc (Figure 1A, leftevier Inc.
Cell Host & Microbe
Crystal Structures of a Protease from Chlamydiaepanel). N-terminal peptide sequencing (data not shown) indi-
cated that the mature CPAFc starts at Gly284 as previously re-
ported (Dong et al., 2004b), whereas CPAFc1 starts at Arg243
andCPAFc2 starts at Val265. The sequential autocatalytic cleav-
age of CPAF was concentration dependent (Figure 1A, right
panel), suggesting that protein concentration may be critical
for CPAF activation in vivo (see Discussion). In addition, environ-
mental factors such as pH and salt concentration might also
affect CPAF activation. To test whether the autocleaved CPAF
is active, we compared the autocleaved CPAF with zymogen
CPAF for their ability to cleave RFX5, a known cellular target of
CPAF in Chlamydia-infected cells (Zhong et al., 2001). CPAF
after autocleavage (lanes 2–9), but not the zymogen (lane 1), rap-
idly processed RFX5 into smaller fragments (Figure 1B), indicat-
ing that autocleavage of CPAF induces its activation. A similar re-
sult was also obtainedwhen anN-terminal fragment of RFX5was
used as the substrate (Figure S1 available online). TheCPAF-cat-
alyzed cleavage of RFX5 was sensitive to the inhibition by lacta-
cystin (Figure 1C), a proteasome inhibitor (Fenteany et al., 1995)
known to inhibit CPAF activity (Zhong et al., 2001).
CPAF zymogen exhibited a molecular weight corresponding
to the predicted 66 kDa under the gel filtration assay
(Figure 1D). In contrast, the mature CPAF was eluted at the po-
sition of a molecular weight of about 120 kDa, although the ma-
ture CPAF is supposed to be shorter than the zymogen due to re-
moval of about 40 amino acids during maturation. These results
indicate that CPAF activation is accompanied by formation of
a stable homodimer in solution.
CPAF Is a Ser Protease with Two Subunits
and a Water-Mediated Catalytic Triad
To understand the catalysismechanismof CPAF, we determined
its crystal structure. Because of its higher resolution, we limit our
discussions to the structure of CPAF crystallized in P212121
(Table S1).
The mature CPAF consists of two structural domains, repre-
senting CPAFn and CPAFc (Figure 2A). The N terminus of CPAFn
forms a three-helix bundle (a1, a3, and a4) followed by a short
b strand (b1). At the other end of CPAFn is a severely twisted
five-stranded b sheet (b3, b4, b5, b7, and b8). Located between
the three-helix bundle and the b sheet are a short three-stranded
b sheet (b2, b6, and b9) and two a helices (a5 and a6) that are
almost perpendicular to each other. At one end of CPAFc is
a six-stranded b sheet (b10, b11, b12, b13, b15, and b16) flanked
by helices a8, a9, and a13 on one side and a15 on the other. In
the middle of CPAFc are four b strands (b14, b17, b18, and b19)
(Figure 2A). b18 forms an antiparallel b sheet with b1 from
CPAFn, whereas b14 and the N terminus of the long loop linking
a12 and b15 contact with the three a helices (a10, a11, and a12)
located at the other end of CPAFc (Figure 2A).
Interaction between CPAFn and CPAFc (heterodimerization) is
mediated by multiple regions of contacts. Between the two sub-
units is a large groove (Figure S2), which is presumably the active
site of CPAF. The N-terminal three-helix bundle appears to play
a prominent role in CPAF heterodimerization, because it not only
interacts with b18 and its preceding loop, but also, at its one end,
stacks against around the end of b14 and the start of b19 in
CPAFc (Figure 2A). CPAF heterodimerization also results from
package of the start of a6 against the two loops following b15Cell Hostand b16. Additionally, interactions of the short a helix a14 from
CPAFc with b3 and b4 from CPAFn provide further binding affin-
ity for CPAF heterodimerization (Figure 2A).
DALI search identified D1P, a member of the C-terminal pro-
cessing peptidases (CPPs) (Rawlings et al., 2008), from plant
as the closest homolog of CPAF, with an rmsd of 1.75 A˚ over
156 Ca atoms of CPAFc (Figure 2B), mainly clustering around
the primary sequence-conserved portion. This is consistent
with the genomics study showing that Chlamydiaceae possess
a high proportion of genes with highest similarity to the se-
quences of plant genes (Stephens et al., 1998). Ser372 and
Lys397 that form the catalytic dyad in D1P (Liao et al., 2000)
are well superimposed with the highly conserved (Figure S3)
Ser499 and His105 in CPAF, respectively (Figure 2B). There
are no other polar residues close enough to hydrogen bond
with Ser499 or His105. These results suggest that CPAF is
a Ser protease that utilizes Ser499 and His105 for its catalytic ac-
tivity (Figure 2C). Consistently, mutations of either of these two
residues completely abolished the ability of CPAF to autopro-
cess and cleave RFX5 (Figure 2D). Although CPAF lacks an
Asp residue to form a catalytic triad as seen in a classic Ser pro-
tease (Hedstrom, 2002), a water molecule-mediated hydrogen
bond between His105 and Glu558 (Figure 2C) may assist the for-
mer in activating Ser499 for the catalytic activity of CPAF. Sup-
porting its role in the catalytic reaction, the mutant E558Q failed
to autocleave and process RFX5 even after a prolonged incuba-
tion time (Figure 2D). Although DALI did not identify tricorn
(Tamura et al., 1996), another member of CPPs, as a structural
homolog of CPAF, three residues from its catalytic tetrad (Brand-
stetter et al., 2001), His746, Ser965, and Glu1023, were well
superimposed with those of CPAF in the active site (Figure 2E).
Moreover, the water molecule is located close to Ser745
(Figure 2E), another residue from the catalytic tetrad of tricorn,
further supporting that His105, Ser499, Glu558, and the water
molecule form a water-mediated catalytic triad of CPAF (Fig-
ure 2C). Our structural observations and biochemical analyses
confirm that CPAF is a Ser protease, and we suggest that catal-
ysis may be aided by a water-mediated catalytic triad.
Homodimeric Assembly of the Mature CPAF
In the crystals, each asymmetric unit contains two mature CPAF
molecules, and their interaction is predominantly mediated by
the packing of a1and b17 together with its preceding loop from
each monomer (Figure 3A). In each monomer, Phe45, Val52,
and Pro534 form extensive hydrophobic contacts with their
neighboring residues from the other one (Figure 3B). Addition-
ally, CPAF homodimerization also involves interactions of a7
and its following loop from one monomer with CPAFc from the
other (Figures 3A and 3C).
To assess the functional significance of CPAF homodimeri-
zation, we made mutations for the residues at the homodimer
interface and assayed the mutants for their oligomerization sta-
tus and catalytic activity. One of these mutants, F45A, eluted
from size exclusion column at monomer position (Figure 3D,
left panel), was unable to autocleave (Figure 3D, top right)
and process RFX5 (Figure 3D, bottom right). By contrast, the
mutation V73D outside of the homodimer interface generated
no effect on its autocleavage, homodimerization, and process
of RFX5 (Figure 3D, middle panel). These results indicate that& Microbe 4, 529–542, December 11, 2008 ª2008 Elsevier Inc. 531
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Crystal Structures of a Protease from ChlamydiaeFigure 2. CPAF Is a Ser Protease with a Water-Mediated Catalytic Triad
(A) A stereo view of structure of one mature CPAF molecule. The two subunits of CPAF, CPAFn (residues 25–239), and CPAFc (residues 284–601) are colored in
salmon and blue, respectively. The C terminus of CPAFn andN terminus of CPAFc are indicated by ‘‘Nc’’ and ‘‘Cn,’’ respectively. The catalytic residues are shown
in stick and magenta.
(B) CPAFc exhibits a similar fold to that of D1P. CPAFc and D1P are shown in blue and light orange, respectively.
(C) The active site of CPAF. Omit electron density (2d) for the residues around the active site of CPAF.
(D) Mutations of the catalytic triad abolish CPAF autocleavage and proteolytic cleavage of RFX5. (Top) For WT or various CPAF mutants, shown on the left and
right are the samples before and after incubation (for 6 hr) at room temperature, respectively. (Bottom) Sample shown on the top panel was mixed with RFX5 and
incubated at 4C for 10 min. The residual RFX5 was visualized by Coomassie blue staining following SDS-PAGE.
(E) Superposition of CPAF with tricorn around the active site. Residues from CPAF and tricorn are shown in magenta and gray, respectively.532 Cell Host & Microbe 4, 529–542, December 11, 2008 ª2008 Elsevier Inc.
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Crystal Structures of a Protease from ChlamydiaeCPAF homodimerization, even transiently, may be required for
its autocleavage. This conclusion is not necessarily inconsis-
tent with our observation that formation of a stable CPAF
homodimer is induced by its autocleavage (Figure 1D). This is
because the wild-type monomeric zymogen may be able to
form a transient homodimer, especially at a high concentration,
allowing the dimerized CPAF zymogen to possess marginal ac-
tivity and process each other. The initial processing, in return,
further induces stable homodimerization that is required for
the full activity of CPAF. It was suggested (Paschen et al.,
2008) that CPAF activation may mimic that of initiator caspases
in which proximity-dependent transient homodimerization fol-
lowed by the formation of a stable homodimer (Boatright
et al., 2003; Donepudi et al., 2003; Riedl and Salvesen, 2007;
Yan et al., 2006) is required their full activity. Our data further
strengthen this idea.
Figure 3. Homodimeric Assembly of CPAF
(A) CPAF forms a homodimer in the crystals. Two different views of the CPAF homodimer in the crystal structure. The two regions involved in CPAF homodime-
rization are highlighted in red and blue frames. The three catalytic residues are shown in stick representation.
(B and C) The detailed interactions around the two regions in (A) highlighted red and blue, respectively.
(D) The monomeric CPAF mutant fails to autocleave and process RFX5. Shown at the bottom right is the residual RFX5 after incubation with the corresponding
protein shown on the top at 4C for 10 min.Cell Host & Microbe 4, 529–542, December 11, 2008 ª2008 Elsevier Inc. 533
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Crystal Structures of a Protease from ChlamydiaeAutoinhibition of CPAF Zymogen by an Internal
Inhibitory Segment
To understand CPAF activation mechanism, we determined the
crystal structure of a CPAF zymogen (S499A) (Table S1). The two
CPAF zymogen molecules in each asymmetric unit do not form
a homodimer as observed in the mature CPAF (data not shown),
but the overall structure of a single CPAF zymogen is similar to
that of its mature form (Figure 4A). The most striking difference
between them is that the active site of CPAF zymogen is blocked
by a peptide (residues 258–283) (Figure 4A), completely filling the
Figure 4. An Internal Inhibitory Segment Binds to the Active Site of CPAF and Blocks Its Homodimerization
(A) Superposition of one CPAF zymogen molecule (slate) with the homodimer of the mature CPAF. The well-ordered peptide (residues 258–283) from zymogen
absent in the mature CPAF is shown in cyan, whereas the red dashed line (residues 223–257) represents the disordered peptide in CPAF zymogen.
(B) Overall view of the catalytic groove in CPAF zymogen (represented by its electrostatic surface) bound by the peptide.
(C) The detailed interactions between N terminus of the inhibitory peptide with CPAF active site.
(D) An isolated peptide derived from the inhibitory segment interacts with the mature CPAF and inhibits its proteolytic activity. GST-fused peptide (residues 258–
283) with mutation as indicated was used to pull down themature CPAF. (Left) After extensive washing, the bound proteins visualized by Coomassie blue staining
following SDS-PAGE are shown. (Right) The activity of CPAF to degrade RFX5 is inhibited by the peptide L259E.
(E) First cleavage of CPAF promotes its homodimerization. Shown on the left panel is superposition of the gel filtration chromatograms for theCPAFmutant S499A
cleaved by the mature CPAF, uncleaved S499A, and F45A cleaved by the mature CPAF. S499A and F45A were incubated with the mature form CPAF at room
temperature for 6 hr before subjected to gel filtration assay.534 Cell Host & Microbe 4, 529–542, December 11, 2008 ª2008 Elsevier Inc.
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Crystal Structures of a Protease from Chlamydiaeactive site of CPAF (Figure 4B). Recognition of this peptide by the
active site is dominated by two regions of contacts. One primar-
ily involves hydrophobic contacts of the N-terminal rigid coil
against the core domain of CPAF. At its center, Met264 nicely
fits into the hydrophobic pocket formed by Val378, Cys500,
Gly525, F527, and the Ca atom of Ala499. Additionally, a pair
of main-chain hydrogen bonds is made between Met264 and
Gly376 (Figure 4C). Van der Waals contacts of three bulky resi-
dues, Phe268, Trp269, and Tyr276, with their respective neigh-
boring residues dominate interactions of the other binding region
(data not shown).
The structure reveals that CPAF zymogen is inactive because
the substrates are unable to gain access to the substrate-bind-
ing pocket (Figure 4B). To test whether the isolated peptide inter-
acts with the mature CPAF, we made a peptide mutant L259E,
as its wild-type was efficiently cleaved by the mature CPAF
(Figure S4). The peptide mutant was significantly compromised
in its cleavage by CPAF (Figure S4), but they still interacted
with each other (Figure 4D, left panel). As expected, the proteo-
lytic activity of CPAF to degrade RFX5was substantially inhibited
by the peptide mutant L259E (Figure 4D, right panel). Supporting
the structural observation (Figure 4C), the peptidemutantM264E
showed no detectable interaction with the mature CPAF
(Figure 4D, left panel).
Residues 223–257 preceding the peptide bound to the active
site have no clear electron density in CPAF zymogen, but struc-
tural comparison indicates that they wobble around one CPAF
homodimer interface (Figure 4A). Thus, the covalent linkage in
this interdomain region would conceivably impose a structural
hindrance on CPAF homodimerization, which can be partially re-
lieved through cleavage after Met242. In support of this hypoth-
esis, the catalytic mutant S499A, following processing by the
active CPAF, was induced to shift to a higher molecular weight
(Figure 4E, left panel), indicating that cleavage of this site may
further stabilize the transient homodimer of CPAF. By contrast,
the monomeric mutant F45A was eluted only at the position of
monomer even after cleavage by the active CPAF (Figure 4E,
left panel). Interestingly, although both S499A (Figure 4E, second
panel from left) and F45A (Figure 4E, right panel) can be cleaved
by the mature CPAF to generate CPAFc1 and CPAFn, they failed
to undergo further processing and achieve full activation. Taken
together, these results demonstrate that the internal segment
(residues 243–283, referred to as the inhibitory segment hereaf-
ter) blocks substrate binding and sequesters CPAF in a mono-
meric state.
Assembly of the Catalytic Triad Induced by an
Activation Switch upon CPAF Homodimerization
In CPAF zymogen, S499A is located immediately underneath the
carbonyl carbon atom of Met264 (Figure 4C), suggesting that the
peptide bond between Met264 and Val265 can be nucleophili-
cally attacked by Ser499. Indeed, an intermediate (Figure 1A, la-
beled as CPAFc2) was generated by cleavage after Met264.
Thus, the catalytic nucleophile and its attacked atom are already
properly positioned in the dormant CPAF. However, autopro-
cessing of the second cleavage site was always dependent on
the first one after Met242 (Figures 1A and 3D), which can facili-
tate CPAF homodimerization (Figure 4E). Additionally, the
cleaved monomeric mutant F45A was unable to undergo furtherCell Hostprocessing (Figure 4E). These results strongly suggest that CPAF
homodimerization triggers conformational changes required for
its full catalytic activity.
Indeed, dramatic conformational changes occur to residues
Val550–Glu559 (loop L1) (Figure 5A). Following homodimeriza-
tion, the N terminus (residues 550–556) of this loop swings about
40 degrees toward a13, allowing Arg551 to salt bond with
Asp510 and make van der Waals contact with Val506
(Figure 5A). By contrast, the C terminus of this loop (residues
557–559) is turned inward toward the active site of CPAF and
packs against the loop L2 harboring Ala524 (Figure 5A). In partic-
ular, Glu558 moves about 8.0 A˚ toward His105 (Figure 5A), en-
abling them to form a water-mediated hydrogen bond. On the
other hand, interaction of the C terminus of L1 with loop L2 in
the mature CPAF causes flipping of Ala524 (Figure 5B), which
likely, in turn, drives the side chain of His105 to rotate about
90 degrees. This not only shortens the distance between
His105N32 and Ser499Og, but also allows His105N32 to be prop-
erly oriented (Figure 5B), making it possible for them to form a
hydrogen bond. These structural analyses indicate that confor-
mational changes in CPAF following homodimerization induce
assembly of its water-mediated catalytic triad.
Then what is the driving force to trigger the conformational
changes in L1 during CPAF homodimerization? In the mature
CPAF, the C terminus (residues 223–239) of CPAFn from one
molecule interacts with CPAFc from the other (Figure 3C). In con-
trast, this segment exhibits no clear electron density and is sup-
posed to be disordered in CPAF zymogen. Structural compari-
son indicates that this peptide from one CPAF monomer would
clash with L1 from the other one if the conformation of the latter
remained unchanged during homodimerization (Figure 5C).
Thus, this peptide likely acts as a trigger to initiate conforma-
tional changes in L1 that eventually lead to assembly of the
water-mediated catalytic triad. (Therefore, we designate this
peptide as an activation switch.) In support of this, a CPAF
mutant with a deletion of six residues (234–239) from the activa-
tion switch that makes it too short to reach L1, was unable to
autocleave even incubated at room temperature for 6 hr
(Figure 5D). Similar results were also obtained for the mutations
of Arg551 and Ile557 (Figure 5D). In complete agreement with the
structural observation, the deletion mutant was significantly
compromised in its further processing following cleavage by
the mature CPAF (Figure 5D). But incubation of the cleaved de-
letion mutant at room temperature for a longer time (about 12 hr)
generated a small fraction of the ‘‘mature form’’ of CPAF. Al-
though this mature form of CPAF generated no effect on its
homodimerization, it had a significantly diminished activity of
degrading RFX5 (Figure 5E). As expected, the deletion mutant
lacking the first autocleavage site resulted in its failure to be
processed by the mature CPAF (Figure 5D).
Lactacystin Is a Covalently Bound Inhibitor of CPAF
CPAF was proposed (Zhong et al., 2001) to possess protea-
some-like activity, because its activity could not be blocked by
protease inhibitors other than the proteasome-specific inhibitor
lactacystin (Zhong et al., 2001), an irreversible inhibitor that
blocks proteasome activity through its hydrolyzed product,
clasto-lactacystin b-lactone (omuralide) (Figure 6A) (Dick et al.,
1997; Groll et al., 1997). Inhibition of CPAF by lactacystin was& Microbe 4, 529–542, December 11, 2008 ª2008 Elsevier Inc. 535
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Crystal Structures of a Protease from Chlamydiaefurther verified by our current data (Figure 1C). To elucidate the
inhibition mechanism, we determined the crystal structure of
CPAF complexed with lactacystin (Table S1).
The homodimer observed in the free mature CPAF also exists
in the structure of CPAF-lactacystin complex (Figure S5), indicat-
ing that inhibition of CPAF by lactacystin is not through
Figure 5. CPAF Homodimerization Triggers Assembly of the Water-Mediated Catalytic Triad
(A) Conformational changes occur to loop L1 (residues 550–559) upon CPAF homodimerization. Close-up view of structural comparison around loop L1 between
CPAF zymogen (slate) and its mature form.
(B) Conformational changes in loop L2 (residues 522–527) are induced by those in loop L1. Close-up view of comparison around loop L2 (residues 522–527)
between CPAF zymogen and its mature form.
(C) The activation switch, as labeled, would clash with L1 if the latter remained unchanged following CPAF homodimerization. (Left) The superimposition of
a CPAF homodimer with one CPAF zymogen molecule. (Right) A close-up view of the region highlighted in the red frame on the left.
(D) A shortened activation switch or an unstabilized L1 significantly compromises CPAF autocleavage. For various CPAF mutants, the left lane represents the
sample incubated at room temperature for 6 hr, and the right lane represents the sample cleaved by the active CPAF. For WT CPAF, the left and right lanes
are the samples before and after incubation (for 6 hr) at room temperature, respectively. ‘‘D’’ represents the truncated mutant.
(E) CPAFwith a shortened activation switch still forms a homodimer in solution but exhibits little proteolytic activity. ForWTmature CPAF and the deletion mutant,
protein from fraction 25 shown on the top panel was diluted 5-fold for the activity assay. The assay was performed as described in Figure 1B.536 Cell Host & Microbe 4, 529–542, December 11, 2008 ª2008 Elsevier Inc.
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Crystal Structures of a Protease from ChlamydiaeFigure 6. Lactacystin Covalently Binds to CPAF
(A) Equilibration of lactacystin with clasto-lactacystin b-lactone in solution (omuralide) (Dick et al., 1997).
(B) Omit electron density (2d) around Ser499 in the structure of CPAF-omuralide complex. The model of omuralide (in pink) was built into the density. The side
chain of Ser499 is shown in yellow.
(C) Specific recognition of omuralide by CPAF. The side chains of CPAF are colored in yellow and omuralide in pink. ‘‘SEL’’ represents the ester product formed
between S499 and omuralide.
(D) Structural comparison between CPAF-omuralide (in pink) and proteasome-omuralide (in cyan) complexes. Residues from proteasome and CPAF are
colored in slate and yellow, respectively. Hydrogen bonds in omuralide-CPAF and omuralide-proteasome complexes are shown in red and blue dashed lines,
respectively.disrupting CPAF homodimerization. A difference electron den-
sity map clearly shows that lactacystin binds around Ser499.
The continuous electron density following Ser499Og
(Figure 6B) indicates that it has covalently linked to omuralide,
which can cause irreversible inhibition of CPAF. Supporting
this structural observation, CPAF activity was nearly killed at
higher concentrations of lactacystin (Figure 1C). The covalently
linked complex in the structure may result from the nucleophilic
attack of Ser499Og on the C6 in omuralide, which can be facili-
tated by the hydrogen bond formed between O7 of omuralide
and the amide nitrogen of Gly376 (Figure 6C). This reaction
can result in the formation of an ester bond in the active site of
CPAF. A similar mechanism was proposed in the inhibition of
proteasome by lactacystin (Groll et al., 1997, 2006a), which in-
volves displacement of nucleophilic water molecules by the
C4-hydroxy group generated through opening of the g-lactam,Cell Hostthus blocking the attack of Thr1Og-CO ester bond (Groll et al.,
2006b). In serine proteases, the nucleophilic water is assisted
by the His residue from the catalytic triad for attacking the tran-
sition state intermediate acyl-enzyme (Hedstrom, 2002). Al-
though the nucleophilic water molecule is disordered in the
free active CPAF, it should exist in substrate-enzyme complex
to form a hydrogen bond with H105 and make nucleophilic at-
tack on the acyl-enzyme to complete the hydrolyzing reaction.
In CPAF-lactacystin, the C4-hydroxy group is 3.6 A˚ from
His105N32, suggesting that it may interfere with formation of
the hydrogen bond between His105 and the nucleophilic water
molecule. This would explain, at least in part, why the ester
bond in CPAF-lactacystin complex is not hydrolyzed as in the
case of proteasome-lactacystin complex (Groll et al., 2006a).
The specificity of omuralide for CPAF is determined by both
hydrophobic contacts and hydrogen bonds (Figures 6C).& Microbe 4, 529–542, December 11, 2008 ª2008 Elsevier Inc. 537
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CPAF and proteasome is through highly conserved interactions,
particularly the hydrogen bonds (Figure 6D), indicating that
CPAFmaymimic host proteasome at least in lactacystin binding.
By contrast, Ser protease inhibitors TPCK and PMSF are as un-
likely to form hydrogen bonds with CPAF as those observed in
CPAF-lactacystin complex, because no polar group exists in
their benzene ring. This may provide an explanation of why
CPAF activity is insensitive to them (Zhong et al., 2001). Our re-
sults not only reveal the inhibition mechanism of CPAF by lacta-
cystin, but also provide structural evidence that lactacystin can
inhibit proteases in addition to proteasome.
DISCUSSION
CPAF Defines a Unique Family of Ser Proteases
Structural comparison (Figures 2B and 2E) appears to support
that CPAF is a CPP. However, it is important to note that CPAF
is different than these proteases in that its catalytic residues
are contributed by two distinct subunits. CPPs, in general, rec-
ognize a C-terminal tripeptide including the carboxy terminus
in the substrates to cleave off the C-terminal residues from the
substrates (Rawlings et al., 2008). Although the water-mediated
catalytic triad of CPAF mimics the catalytic tetrad of the tricorn
protease, other residues around the active site are not con-
served. In particular, the two basic residues, Arg131 and
Arg132, important for the tricorn protease to anchor the sub-
strate C terminus (Brandstetter et al., 2002) are not conserved
in the active site of CPAF. CT441 in C. trachomatis was recently
shown to be a CPP (Lad et al., 2007). However, compared to
CT441, CPAF has lower sequence homology to the known
CPPs. The conclusion that CPAF does not belong to the CPP
family is further supported by the following biochemical evi-
dence. First, the C-terminal sequences of the substrates are
not required for their proteolytic cleavage by CPAF. Among the
known CPAF substrates, including RFX5, keratin 8, PUMA (Pirb-
hai et al., 2006), PARP, and Cyclin B1 (Paschen et al., 2008), no
sequence homology exists at their C termini. Second, CPAF
does not seem to process the C termini of its substrates. Both
the N- (Figure S1) and C-terminal (Figure 1B) fragments of
RFX5 were processed into multiple smaller fragments, suggest-
ing that CPAF possesses an endopeptidase activity. This con-
clusion is consistent with the report that CPAF cleaved off both
the N-terminal head and C-terminal tail domains from keratin 8
(Dong et al., 2004a). Third, all three autocleavage sites of
CPAF are located in the middle of its sequence. Thus, CPAF
does not recognize its own C-terminal sequence for autopro-
cessing. The C-terminal carboxylate of CPAF is more than 300
residues away from any of the three autocleavage sites and is,
therefore, unlikely involved in the recognition of the inhibitory
segment for cleavage. This is consistent with the fact that the
C terminus (residues 258–283) of the inhibitory segment can be
cleaved by the mature CPAF (Figure S4), although it shares no
homology with the C-terminal sequence of CPAF full-length mol-
ecule (Figure S3). Finally, the mature CPAF can still bind to Ni
resin via the His tag fused to the C terminus of CPAF, indicating
that the CPAF C terminus was not cleaved during activation. It is
clear that CPAFmay appear tomaintain a structure similar to that
of CPPs but has evolved a distinct enzymatic activity.538 Cell Host & Microbe 4, 529–542, December 11, 2008 ª2008 ElsModel on CPAF Activation
In this current study, we have provided evidence that the highly
purified recombinant CPAF can undergo trans-autocatalytic
cleavage (Figure 1A) and thereby promote homodimer formation
(Figure 4E), leading to conformational changes and formation of
the catalytic triad (Figure 5). This results in further processing of
the internal inhibitory segment to completely free the catalytic
site. The observations that a variant of the inhibitory peptide in-
teracted with CPAF and inhibited its activity (Figure 4D) strongly
support that activation of CPAF is regulated via a multistep
cleavage of the inhibitory segment. This multistep model is con-
sistent with previous in vivo data that an intermediate fragment
recognizable by an anti-CPAFc antibody was repeatedly de-
tected during chlamydial infection (Dong et al., 2004b; Heuer
et al., 2003).
Step 1: Transient homodimerization triggers the first cleav-
age between Met242 and Arg243, promoting the formation of
more stable homodimers of CPAF (Figure 7). Transient homodi-
merization can take place in vitro by increasing concentrations
of CPAF zymogen (Figure 1A). In further support of this possi-
bility, forced clustering of CPAF by fusing to a bacterial gyrase
resulted in CPAF activation in human cells (Paschen et al.,
2008). A transient CPAF homodimer may possess weak activity
to initiate the proteolytic cleavage. In CPAF homodimer, there is
a long distance between the initial cleavage site of one CPAF
molecule and the active site of the other (Figure 3A). Therefore,
we propose that cleavage of this occurs through intertransient
homodimers of CPAF (in trans). Supporting the trans auto-
cleavage are the observations that in vitro autoprocessing of
CPAF is concentration dependent (Figure 1C, right panel)
and the catalytic mutant S499A was processed by the mature
CPAF (Figure 4E). We can further speculate that the driving
force for CPAF activation derives from homodimerization
preceding proteolytic processing. Supporting this hypothesis
is the observation that the monomeric mutant F45A failed to
undergo autoprocessing (Figure 3D). It is noteworthy to point
out that, although CPAF activation in a cell-free system is
initiated strictly via an autoprocessing mechanism, we still
cannot rule out the possibility that other protease(s) or cofac-
tor(s) are involved in CPAF activation in vivo during chlamydial
infection.
Step 2: The initial proteolytic cleavage after Met242 not only
promotes homodimerization of CPAF (Figure 4) but also frees
the activation switch, both of which are required for assembly
of the water-mediated catalytic triad (Figure 5).
Step 3: Assembly of the water-mediated catalytic triad en-
ables CPAF to further cleave the inhibitory segment (Figure 7).
The observation that the catalytic mutant S499A was not
cleaved between Met264–Val265 by the active CPAF
(Figure 4E) strongly suggests that cleavage of this site is in cis.
Removal of residues 243–264 through cleavages of the above
two sites cannot only further enhance homodimerization of
CPAF but also substantially reduce the binding affinity of the in-
hibitory segment with the active site, promoting release of its re-
maining part (265–283) from the active site and subsequent
cleavage after Ser283 (Figure 7). Thus, the three proteolytic
cleavage steps, which each depend on their previous one, result
in complete removal of the inhibitory segment and full activation
of CPAF.evier Inc.
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Activation
The zymogenCPAF is kept dormant by the internal
inhibitory segment (in red and yellow). Formation of
a transient CPAF homodimer leads to autocleav-
age of the first cleavage site after Met242, promot-
ing homodimerization of CPAF. The freed activa-
tion switch (in orange) in CPAFn (salmon) induces
conformational change in loop L1 of CPAFc (blue)
from the other CPAF monomer. Thus, Glu558 in
L1 consequently moves close to His105 (data not
shown), forming a water-mediated catalytic triad
and leading to the cleavage afterMet264. Removal
of the peptide (residues 243–264, in red) dimin-
ishes binding affinity of the inhibitory segment
with the active site of CPAF and promotes release
of the remaining portion (residues 265–283, yellow
dots) and cleavage after Ser283.The structural data suggest that CPAF may mimic caspases
for initiation of its activation, but different mechanisms follow
to achieve their full activation; caspase homodimerization results
in formation of the substrate-binding sites (Riedl and Salvesen,
2007), whereas CPAF’s active site is preformed and homodime-
rization triggers realignment of its catalytic triad. Other Ser or Cys
proteases involving homodimerization can result in formation of
the composite substrate-binding groove (Lorenz et al., 2006) or
a single active site at the homodimerization interface (Wlodawer
and Gustchina, 2000). One exception to this is human cytomeg-
alovirus (HCMV) protease in which homodimerization results in
stabilization of the oxyanion hole (Batra et al., 2001). CPAF differs
from these proteases in that its substrate-binding site in its
zymogen is preformed and CPAF homodimerization triggers
realignment of catalytic triad for its activation. Our results, there-
fore, reveal a distinct mechanism by which homodimerization
regulates the catalytic activity of a Ser protease.
CPAF Activity Regulation in Chlamydial Biology
and Pathogenesis
The complex regulation mechanism for controlling CPAF activity
may have been evolved by Chlamydia as a result of the intricate
chlamydial interactions with host cells. The concentration-
dependent activation cascade of CPAF may provide Chlamydia
additional means for regulating CPAF activity. CPAF does not
accumulate inside chlamydial inclusion to any large amount, al-
though it is synthesized by the organisms inside the inclusion.
The yet to be secreted CPAF can remain dormant due to lack
of critical concentration required for triggering CPAF activation,
thus protecting Chlamydia’s own proteins from the degradation
by CPAF. This assumption gains supports from the finding that,
although CPAF protein was detected inside inclusions as early
as 12 hr postinfection, clear CPAF secretion and activity were
only detected 24 hr after infection (Heuer et al., 2003; Shaw
et al., 2002; Zhong et al., 2001). Chlamydia may have also taken
advantage of the concentration-dependent activation of CPAF to
avoid rapid destruction of host cells when Chlamydia still needsCell Hosthe integrity of host cells for completing its own replication.
Supporting this hypothesis, the overall CPAF activity peaked
36–48 hr after infection, when the amount of CPAF had reached
a plateau in the cytoplasm of the infected cells andmost intracel-
lular chlamydial organisms had already matured into the infec-
tious elementary bodies and were ready to exit the infected cells
(Heuer et al., 2003). The controlled CPAF activation is especially
important during persistent infection, when chlamydial organ-
isms hide inside host cells in a nonproductive and noninfectious
form for long periods of time. Indeed, under persistent infection
conditions, CPAF activity was maintained at a minimal level (He-
uer et al., 2003; Shaw et al., 2002; Zhong et al., 2001).
Substrate Specificity
Although CPAF has been shown to be able to cleave multiple
host proteins, its substrate specificity still remains unknown.
The observations that the C terminus of the inhibitory segment
binds to the active site of CPAF (Figure 4B) and itself can be
cleaved by the active CPAF (Figure S4) indicate that CPAF zymo-
gen essentially represents an enzyme-substrate complex, which
may provide significant insights into the substrate specificity of
CPAF.
Recognition of the peptide by the active site of CPAF is primar-
ily through hydrophobic interactions (Figure 4B). Extensive inter-
actions of Met264 with a hydrophobic pocked around the active
site of CPAF (Figure 4C) indicate that CPAF has a preference for
substrates with hydrophobic residues at P1 position. But due to
the limited size of this pocket, a bulky hydrophobic residue like
Trp would be unfavorable for substrate binding. Interestingly,
recognition of lactacystin is predominantly through the S1 site
(Figure 6C), suggesting that it may play an important role in de-
termining the substrate specificity of CPAF. By contrast, resi-
dues at the positions of P2, P3, and P4 make no contact with their
neighboring residues. Phe260 at P5 position makes extensive
hydrophobic contacts with CPAF (Figure 4C), but mutation of
this residue slightly affected cleavage of the GST-peptide by
the mature CPAF (Figure S4). Interestingly, although the sidet & Microbe 4, 529–542, December 11, 2008 ª2008 Elsevier Inc. 539
Cell Host & Microbe
Crystal Structures of a Protease from Chlamydiaechain of Leu259 at P6 makes no contact with other residues, mu-
tation of this residue L259E significantly compromised its cleav-
age by the mature CPAF (Figure S4) when the peptide (residues
258–283) was used as the substrate.
The side chain of Val265 turns itself outward of the active site
and is not involved in peptide recognition by the active site. Thus,
the residue at the P10 position may not have much influence on
substrate recognition, although the small ones might be pre-
ferred by CPAF. The P20 position is occupied by Pro266 that
faces the bottom of the active site and makes hydrophobic con-
tacts with Phe498 and Pro374 (Figure 4C), thus significantly cir-
cumscribing the size of a residue at this position. It is, therefore,
conceivable that CPAF would prefer small hydrophobic residues
at P20. Like Pro266, His267 at P30 faces the inside of the active site
and is completely buried. But it is positioned in a large enough
hydrophobic pocket to accommodate the bulky hydrophobic
residues like Phe (Figure 4C). Thus, CPAF may recognize more
varied residues at P30 than at P20. Phe268 (at P40) and Trp269
(at P50) interact extensively with the active site of CPAF. Thus,
CPAF can prefer bulky residues at these two positions.
Although more studies, including kinetics and mutagenesis,
are needed to further map the cleavage motifs of CPAF, the
information derived from recognition of the inhibitory peptide
and lactacystin by CPAF should be valuable in identifying addi-
tional substrates of CPAF and designing small molecular inhibi-
tors as the therapeutic agents in a variety of clinical situations.
Although CPAF has been demonstrated to be a virulence factor
in chlamydial pathogenesis, no attenuated chlamydial strains
have been generated due to the difficulty in genetic manipulation
of Chlamydia. Using the knowledge gained from the current
study to develop CPAF-specific inhibitors may represent a viable
approach for attenuating chlamydial pathogenicity.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
All of the constructs were generated by the standard PCR-based cloning strat-
egy, and their identities were confirmed by sequencing. All of the CPAFs
(residues 25–609), wild-type or various mutants, were cloned into the vector
pET30a (Novagen) unless specified otherwise. All of the proteins were ex-
pressed in Escherichia Coli strain BL21 (DE3). The proteins were first purified
on Ni-resin and then further fractionated by anion ion exchange (Source-15Q,
Pharmacia) and gel filtration chromatography (Superdex-200, Pharmacia).
The mutant CPAF S499A protein thus purified was directly used for crystalliza-
tion, whereas the wild-type CPAF was first left at room temperature for 6 hr to
allow it to be fully autoprocessed and then subjected to gel filtration chroma-
tography again. The purified autocleaved CPAF was further concentrated to
10.0 mg/ml for crystallization.
Crystallization and Data Collection
Crystals of the active CPAF, its complex with lactacystin, and mutant S499A
were generated by mixing the complex with an equal amount of well solution
by the hanging-drop vapor-diffusion method. The native active CPAF protein
was crystallized in buffer containing 1.4 M Li2SO4, 0.1 M HEPES (pH 7.0).
The crystals belong to the P212121 space group, with two CPAF molecules
in each asymmetric unit and a unit cell a = 61.30 A˚, b = 152.37 A˚, c = 162.58
A˚, and a = b = g = 90.0. The mutant S499A was crystallized under the condi-
tions of 3.9 M NaNO3, 0.5 M NaCl, 0.08 M KCl, and 0.1 M Bis-Tris propane
(BTP) (pH 8.0). The crystals belong to R32 and have a unit cell a = b =
192.67 A˚, c = 338.87 A˚, and a = b = 90.0, g = 120, with two CPAF molecules
in each asymmetric unit. Crystals of active Se-Met CPAF were generated
under the same conditions as those of the native one but belong to the
P41212 space group, with two CPAF molecules in each asymmetric unit and540 Cell Host & Microbe 4, 529–542, December 11, 2008 ª2008 Elsa unit cell a = b = 124.87 A˚, c = 241.51 A˚, and a = b = g = 90.0. Lactacystin
(2 mM) was mixed with an equal volume of CPAF and incubated at 4C for
6 hr and then used for crystallization. The crystals of the lactacystin-CPAF
complex were generated in buffer-containing 15.0% PEG 4000 (v/v), 0.6 M
MgCl2, 0.1 M Tris (pH 8.5). Crystals were equilibrated in a cryoprotectant
buffer-containing reservoir buffer plus 15.0% glycerol (v/v). The native and
MAD data sets were collected at the BSRF (Beijing, China) beamline 3W1A
and processed using the software Denzo and Scalepack (Otwinowski and
Minor, 1997).
Structure Determination and Refinement
SOLVE (Terwilliger, 2003) was used to locate the positions of selenium. The ini-
tial phases from SOLVE were further improved by solvent flattening using
RESOLVE (Terwilliger, 2003). A model was built into the MAD electron density
map using the program O (Jones et al., 1991). The initial model was first sub-
jected to rigid body refinement and then annealing, position, and B factor re-
finement using CNS (Bru¨nger et al., 1998) against the MAD data set. The crys-
tal structures of active native CPAF, CPAF zymogen, and CPAF-lactacystin
complex were determined by molecular replacement using the program
MolRep. The final refined atomic model in the active native CPAF contains res-
idues 31–239, 284–601, and 427 water molecules, whereas, in the CPAF mu-
tant, S499A contains residues 31–222 and 258–604 with no water molecules
added.
In Vitro Enzymatic Activity Assay
The assay was carried out at 4C in buffer containing 25 mM Tris (pH 8.0),
150 mM NaCl, and 3 mM dithiothreitol (DTT). Two RFX5 fragments (residues
1–180 and 181–616) were used as the substrates of CPAF at a concentration
of50.0 mM. The mature CPAF was purified to homogeneity and used in each
reaction at 0.5 mM. Reaction samples were taken out at different time points
and applied to SDS-PAGE followed by Coomassie blue staining. To generate
the variant of themature formCPAFwith deletion of six residues (234–239), the
active CPAF was first incubated with CPAF zymogen containing deletion of six
residues (234–239) for 6 hr at room temperature. The CPAF zymogen thus
treatedwas completely cleaved into CPAFc1 andCPAFn. The reactionmixture
was further subjected to anion ion exchange chromatography (Q-Sepharose,
Pharmacia). Fractions containing CPAFc1 and CPAFn were collected and left
at room temperature for 12 hr to generate more mature form CPAF and then
subjected to gel filtration chromatography. The mature CPAF thus generated
was used for its activity assay.
For the inhibition of CPAF by lactacystin (Sigma), a progressively increasing
amount of lactacystin (0.06, 0.12, 0.24, 0.48, 0.96, and 1.92 mM) was used.
The peptide (residues 258–283 from CPAF), wild-type or various mutants,
were cloned into vector pGEX-6P-1 (Pharmacia) and purified using glutathione
sepharose 4B. After removal of glutathione S-transferase (GST) by PreScission
protease, the peptide was subjected to gel filtration for further purification. An
increasing amount of the peptide with the mutation M264E (0.03, 0.06, 0.12,
and 0.24 mM) thus purified was used for inhibition assay. The mature CPAF
was incubated with lactacystin (for 30 min) or peptide (for 5 min) before the
substrate was introduced.
Gel Filtration Assay
CPAF zymogens, wild type or its various mutants (S499A, F45A, and V73D),
were subjected to gel filtration analysis after being purified by anion ion ex-
change (Source-15Q, Pharmacia). The CPAF mutants S499A and F45A were
cleaved by the active CPAF at room temperature for 6 hr. The cleaved mutants
were subjected to anion ion exchange (Source-15Q, Pharmacia) and gel filtra-
tion chromatography (Superdex-200, Pharmacia) to remove the active CPAF.
Individual protein purified to homogeneity was incubated in assay buffer
25 mM Tris (pH 8.0), 150 mM NaCl, and 3 mM DTT for 10 min at 4C. The
proteins purified from anion ion exchange were subjected to gel filtration anal-
ysis (Superdex 200, Amersham Biosciences). Samples taken from relevant
fractions were applied to SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and visualized by Coomassie blue staining.
Pull-Down Assay
GST-mediated pull-down assay was used to investigate the interaction
between the peptide (residues 258–283) mutants with the mature CPAF.evier Inc.
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one sepharose and incubated with mature CPAF at 4C for 5 min. After exten-
sive washing using buffer containing 25 mM Tris (pH 8.0), 150 mM NaCl, and
3.0 mM DTT, the bound proteins were visualized by Coomassie staining
following SDS-PAGE.
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